Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, Editas Medicine, Inc. (NASDAQ:EDIT) shares are down a considerable 25% in the last month, which continues a horrid run for the company. Instead of being rewar

Simply Wall StApr 23 20:04

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in Vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one

GlobeNewswireApr 23 04:31

Leber Congenital Amaurosis Pipeline Insight 2024, Featuring Key Players ProQR Therapeutics, Editas Medicine, Atsena Therapeutics, Applied Genetic Technologies, IVERIC Bio and MeiraGTx

Yahoo FinanceApr 22 19:51

Possible Bearish Signals With Editas Medicine Insiders Disposing Stock

The fact that multiple Editas Medicine, Inc. (NASDAQ:EDIT) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When evaluating in

Simply Wall StApr 6 20:06

Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?

Seeking AlphaApr 2 23:36

Biotech Roundtable: Is CRISPR All Its Cracked up to Be?

Seeking AlphaMar 26 23:43